%0 Journal Article
%9 ACL : Articles dans des revues avec comité de lecture répertoriées par l'AERES
%A Ayouba, Ahidjo
%A Thaurignac, Guillaume
%A Morquin, D.
%A Tuaillon, E.
%A Raulino, R.
%A Nkuba, A.
%A Lacroix, Audrey
%A Vidal, Nicole
%A Foulongne, V.
%A Le Moing, V.
%A Reynes, J.
%A Delaporte, E.
%A Peeters, Martine
%T Multiplex detection and dynamics of IgG antibodies to SARS-CoV2 and the highly pathogenic human coronaviruses SARS-CoV and MERS-CoV
%D 2020
%L fdi:010079419
%G ENG
%J Journal of Clinical Virology
%@ 1386-6532
%K COVID-19 ; SARS-CoV2 ; SARS ; Luminex ; Serology
%K FRANCE
%M ISI:000552972500016
%P art. 104521 [6]
%R 10.1016/j.jcv.2020.104521
%U https://www.documentation.ird.fr/hor/fdi:010079419
%> https://horizon.documentation.ird.fr/exl-doc/pleins_textes/divers20-08/010079419.pdf
%V 129
%W Horizon (IRD)
%X Background: Knowledge of the COVID-19 epidemic extent and the level of herd immunity is urgently needed to help manage this pandemic. Methods: We used a panel of 167 samples (77 pre-epidemic and 90 COVID-19 seroconverters) and SARS-CoV1, SARS-CoV2 and MERS-CoV Spike and/or Nucleopcapsid (NC) proteins to develop a high throughput multiplex screening assay to detect IgG antibodies in human plasma. Assay performances were determined by ROC curves analysis. A subset of the COVID-19+ samples (n= 36) were also tested by a commercial NC-based ELISA test and the results compared with those of the novel assay. Results: On samples collected >= 14 days after symptoms onset, the accuracy of the assay is 100 % (95 % CI: 100-100) for the Spike antigen and 99.9 % (95 % CI:99.7-100) for NC. By logistic regression, we estimated that 50 % of the patients have seroconverted at 5.7 +/- 1.6; 5.7 +/- 1.8 and 7.9 +/- 1.0 days after symptoms onset against Spike, NC or both antigens, respectively and all have seroconverted two weeks after symptoms onset. IgG titration in a subset of samples showed that early phase samples present lower IgG titers than those from later phase. IgG to SARS-CoV2 NC cross-reacted at 100 % with SARS-CoV1 NC. Twenty-nine of the 36 (80.5 %) samples tested were positive by the commercial ELISA while 31/36 (86.1 %) were positive by the novel assay. Conclusions: Our assay is highly sensitive and specific for the detection of IgG antibodies to SARS-CoV2 proteins, suitable for high throughput epidemiological surveys. The novel assay is more sensitive than a commercial ELISA.
%$ 052 ; 050